| アブストラクト | INTRODUCTION: Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice. OBJECTIVE: This study explores the syndromic burden of impulsivity induced by pramipexole and aripiprazole, pinpointing key symptoms for targeted mitigation. METHODS: An event-event Information Component (IC) on the FDA Adverse Event Reporting System (FAERS) (January 2004 to March 2022) identified the syndrome of events disproportionally co-reported with impulsivity, separately for pramipexole and aripiprazole. A greedy-modularity clustering on composite network analyses (positive pointwise mutual information [PPMI], Ising, Phi) identified sub-syndromes. Bayesian network modeling highlighted possible precipitating events. RESULTS: Suspected drug-induced impulsivity was documented in 7.49% pramipexole and 4.50% aripiprazole recipients. The highest IC concerned obsessive-compulsive disorder (reporting rate = 26.77%; IC median = 3.47, 95% confidence interval [CI] = 3.33-3.57) and emotional distress (21.35%; 3.42, 3.26-3.54) for pramipexole, bankruptcy (10.58%; 4.43, 4.26-4.55) and divorce (7.59%; 4.38, 4.19-4.53) for aripiprazole. The network analysis identified delusional jealousy and dopamine dysregulation sub-syndromes for pramipexole, obesity-hypoventilation and social issues for aripiprazole. The Bayesian network highlighted anxiety and economic problems as potentially precipitating events. CONCLUSION: The under-explored consequences of drug-induced impulsivity significantly burden patients and families. Network analyses, exploring syndromic reactions and potential precipitating events, complement traditional techniques and clinical judgment. Characterizing the secondary impact of reactions will support informed patient-centered decision making. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2024/8/16 |
|---|
| 投稿者 | Fusaroli, Michele; Polizzi, Stefano; Menestrina, Luca; Giunchi, Valentina; Pellegrini, Luca; Raschi, Emanuel; Weintraub, Daniel; Recanatini, Maurizio; Castellani, Gastone; De Ponti, Fabrizio; Poluzzi, Elisabetta |
|---|
| 組織名 | Pharmacology Unit, Department of Medical and Surgical Sciences, University of;Bologna, Bologna, Italy. michele.fusaroli2@unibo.it.;Unit of Medical Physics, Department of Medical and Surgical Sciences, University;of Bologna, 40138, Bologna, Italy.;Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of;Bologna, Via Belmeloro 6, 40126, Bologna, Italy.;Bologna, Bologna, Italy.;Hertfordshire Partnership NHS University Foundation Trust, Highly Specialised OCD;and BDD Service, Rosanne House, Parkway, Welwyn Garden City, Hertfordshire, UK.;School of Life and Medical Sciences, University of Hertfordshire, Hatfield,;Hertfordshire, UK.;Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.;Parkinson's Disease Research, Education and Clinical Center (PADRECC),;Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39147961/ |
|---|
